Publications by the researcher in collaboration with Isabel Martín Herranz (14)

2023

  1. Lipid profile changes associated with antiretroviral therapies in a real-world cohort

    Farmacia Hospitalaria, Vol. 47, Núm. 5, pp. 210-217

  2. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

2021

  1. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 1, pp. 16-21

2020

  1. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice

    Journal of Medical Virology, Vol. 92, Núm. 12, pp. 3488-3498

  2. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 1 e, pp. E41-E47

2019

  1. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

  2. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  3. Nocardiosis pulmonar tratada con tedizolid

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 43, Núm. 6, pp. 208-210

  4. Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis

    Telemedicine and e-Health, Vol. 25, Núm. 5, pp. 399-406

  5. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

2017

  1. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446

  2. Intelligent MONitoring System for antiviral pharmacotherapy in patients with chronic hepatitis C (SiMON-VC)

    Farmacia Hospitalaria, Vol. 41, Núm. 1, pp. 68-88